Bausch Health / Renova
TRETINOIN EMOLLIENT CREAM 0.02%
The only prescription anti-ageing product in this register whose own label tells you, in capital letters, that it does not reverse photoageing. It is also the only one that publishes what happened to the people who got the vehicle instead. Both facts are worth more than the drug.
Worth buying for a specific person with a specific problem. Read who.
ASSESSED ON 75% OF THE MODEL. 2 CRITERIA LEFT UNSCORED — SEE SCORING FOR WHY.
We earn nothing on this link. Before you buy the brand, ask your prescriber what generic tretinoin 0.025% cream would cost you — it is the same molecule at a slightly higher strength.
The verdict
This is the FDA-approved topical for facial wrinkles, and its label is the most honest document in this entire register. The indication statement contains the sentence: 'RENOVA (tretinoin cream) 0.02% DOES NOT ELIMINATE WRINKLES, REPAIR SUN-DAMAGED SKIN, REVERSE PHOTOAGING, or RESTORE MORE YOUTHFUL or YOUNGER SKIN.' That is the manufacturer, in its own approved labelling, disowning every phrase the rest of the category sells on.
The efficacy data are correspondingly modest and correspondingly published. Across four vehicle-controlled trials in lightly pigmented subjects, 60% of Renova users saw some improvement in fine wrinkling at 24 weeks against 39% on vehicle alone. The gap is real — 21 points, and it held up statistically — but 39% of people improved on a moisturiser plus sunscreen plus sun avoidance, and only 10% on the drug reached what the trial called moderate improvement. Two of the five trials demonstrated efficacy. No two of them demonstrated efficacy for coarse wrinkling, mottled hyperpigmentation, tactile roughness or laxity, which is why the indication covers fine wrinkles and nothing else.
One finding deserves to be lifted out. In the single trial run in darkly pigmented subjects with Fitzpatrick types IV to VI, 29% improved on Renova against 43% on vehicle. The drug did worse than the cream it was dissolved in. The label says so, notes that the study was small, and does not bury it. No telehealth compounder in this register has published a subgroup that contradicts its own product.
What stops this being a straightforward recommendation is arithmetic. A 40 g tube of brand Renova runs around $319 cash, and there is no approved generic of the 0.02% strength. Generic tretinoin cream starts near $38. Renova's advantage over generic tretinoin is an emollient vehicle and an indication written for wrinkles rather than acne — it is not a different molecule, and no trial has compared the two on irritation or effect. You are largely paying for the indication.
- The concentration, the fill weight and the full excipient list are all on the carton.
- Five vehicle-controlled trials with published results, including the trials that failed.
- Publishes the vehicle arm, so you can see what sunscreen and moisturiser alone achieved: 39%.
- Publishes a subgroup in Fitzpatrick IV–VI skin in which the drug performed worse than vehicle.
- States in the indication itself that it does not reverse photoageing or restore younger skin.
- States that effects may be lost within 12 weeks of stopping — the honest version of a retention message.
- States that safety beyond 52 weeks of daily use has not been established, rather than implying indefinite use is proven.
- No subscription. It is a prescription and a tube, and you stop when you decide to.
- Names the drug interactions that matter — thiazides, tetracyclines, fluoroquinolones, phenothiazines, sulfonamides — as photosensitising.
- The effect is small: 10% of users reached moderate improvement, against 3% on vehicle.
- Only two of five trials demonstrated efficacy for the indication that was granted.
- No evidence of benefit for coarse wrinkling, mottled hyperpigmentation, roughness or laxity.
- In darkly pigmented skin, the single available trial favoured vehicle over drug.
- 0.02% has never been compared against the older 0.05% formulation for either efficacy or irritation.
- Around $319 a tube against roughly $38 for generic tretinoin, for the same molecule.
- Effectively never covered by insurance, because the indication is cosmetic.
- Patients with actinic keratosis or a history of skin cancer were excluded from the trials, so the population most likely to want a retinoid has no data.
- Beyond 52 weeks the label offers nothing, and this is a product people use for decades.
Every active, assessed
- Tretinoin0.02%
Retinoic acid receptor agonist — increases epidermal turnover, and over months increases procollagen deposition in the papillary dermis
- BENCHMARK
- 0.025% to 0.1% is the range used in acne trials; 0.05% was the earlier Renova strength
- ASSESSMENT
- The lowest strength of tretinoin any regulator has approved for a facial indication, chosen for tolerability in a population applying it indefinitely rather than for potency. The label states outright that no study has compared irritation or efficacy between 0.02% and the older 0.05% formulation, so the trade-off you are being offered has never been quantified.
| ACTIVE | CONC. | BENCHMARK | ASSESSMENT |
|---|---|---|---|
| TretinoinRetinoic acid receptor agonist — increases epidermal turnover, and over months increases procollagen deposition in the papillary dermis | 0.02% | 0.025% to 0.1% is the range used in acne trials; 0.05% was the earlier Renova strength | The lowest strength of tretinoin any regulator has approved for a facial indication, chosen for tolerability in a population applying it indefinitely rather than for potency. The label states outright that no study has compared irritation or efficacy between 0.02% and the older 0.05% formulation, so the trade-off you are being offered has never been quantified. |
Scoring
- EVIDENCE FOR THE ACTIVEWEIGHT 30%72/100
Five vehicle-controlled trials, 656 evaluable subjects, 24 weeks, published endpoints and a published vehicle arm — the strongest evidence base for any product in this register. Marked down because the effect is small and narrow: only two of five trials demonstrated efficacy, the indication covers fine wrinkles alone, and the one trial in Fitzpatrick IV–VI skin favoured vehicle.
- FORMULATION INTEGRITYWEIGHT 20%70/100
An emollient oil-in-water cream built to make daily tretinoin tolerable rather than to maximise delivery, which is the right objective for a product taken indefinitely. Manufactured to pharmaceutical standard with a stated fill weight and a full excipient list. Held back because the strength sits below every concentration in the acne trial literature and the label concedes no comparison against 0.05% was ever run.
- DISCLOSUREWEIGHT 15%96/100
The benchmark the rest of this register is failing against. Concentration on the carton. Fill weight on the carton. Full excipient list. Every efficacy category published including the ones that failed. A vehicle arm published alongside the drug arm. A subgroup published in which the drug underperformed vehicle. An explicit statement of what the product does not do. Short of a published cost-per-application, there is nothing left to ask for.
- TOLERANCE IN USEWEIGHT 15%NOT ASSESSED
Not assessed. The label reports severe local erythema, peeling, burning and stinging as expected class effects and warns that patients over 65 may experience slightly more irritation. A panel would be needed to place 0.02% in an emollient base against 0.025% generic cream, which is the comparison that actually matters here.
- TEXTURE & WEARWEIGHT 10%NOT ASSESSED
Not assessed. The emollient base is the product's whole differentiation from generic tretinoin and deserves a panel rather than an assumption.
- COST PER APPLICATIONWEIGHT 10%42/100
Around $319 for 40 g, with no approved generic at this strength and no insurance coverage in practice, because wrinkle indications are treated as cosmetic. Against roughly $38 for a tube of generic tretinoin cream containing more of the same drug. The fill weight is published, so cost per application is at least computable — which is more than most of this register manages — but the answer is poor.
What it is
Tretinoin 0.02% in an emollient oil-in-water cream, approved as an adjunct for the mitigation of fine facial wrinkles in people already using a comprehensive skin care and sun avoidance programme. A 40 g tube, brand only, around $319 cash. It is the reference against which every compounded 'anti-ageing' formula in this register should be read.
Read the indication. All of it.
RENOVA (tretinoin cream) 0.02% DOES NOT ELIMINATE WRINKLES, REPAIR SUN-DAMAGED SKIN, REVERSE PHOTOAGING, or RESTORE MORE YOUTHFUL or YOUNGER SKIN.
FDA-approved labelling, INDICATIONS AND USAGE
The capitals are the manufacturer's, not ours. That sentence sits inside the indication section — not in a footnote, not in a risk disclosure at the bottom of a page, but in the paragraph that defines what the product is for. The same paragraph goes on to note that in the double-blind trials, many patients in the vehicle group achieved the desired effect on fine wrinkling using sunscreen, protective clothing and a non-prescription emollient cream.
Every phrase Renova disowns — reverses photoageing, repairs sun damage, restores younger skin — appears somewhere in the marketing of products we have reviewed at R-06, R-15, R-19 and R-31. Those are compounded formulas, which means no regulator ever assessed the claim. Renova went through the assessment, and what came out the other side was a sentence in capital letters saying no.
The numbers, including the vehicle arm
Four multi-centre trials in lightly pigmented subjects, 24 weeks, graded on a ten-unit scale. Improvement was scored in bands: minimal is a one-unit reduction, mild is two, moderate is three or more. Here is the whole distribution, drug against vehicle.
Renova 0.02% + comprehensive skin protection (N=279) against vehicle cream + the same programme (N=280). Any improvement: 60% against 39%. The drug wins, and the vehicle arm is not nothing — which is the number the rest of this category never shows you.
Two things follow. First, the drug works: 60% against 39% for any improvement, and a threefold advantage at the moderate end, is a genuine effect and it is the reason the approval exists. Second, the honest description of that effect is 'one person in ten got a moderate result after six months' — not 'clinically proven to reverse the signs of ageing'.
The label is also specific about what failed. Of the five trials, two provided adequate demonstration of efficacy for fine wrinkling. For coarse wrinkling, mottled hyperpigmentation, tactile roughness and laxity, no two trials agreed. Those endpoints were measured, they did not replicate, and the indication was written narrowly as a result.
The subgroup nobody else would have printed
A separate single-centre trial enrolled 107 darkly pigmented subjects, mostly African-American, with Fitzpatrick skin types IV to VI. Minimal or mild improvement in fine facial wrinkling was seen in 29% of those using Renova and 43% of those using vehicle.
The label reports it plainly, then adds the appropriate caveat — that the finding may reflect the small size of the study — and leaves it in the document. It is the only instance in fifty-four reviews of a manufacturer publishing a population in which its own product lost to placebo. Set against a register in which day-30 satisfaction surveys are the norm, this is what a real evidence base looks like: it contains results the marketing department would not have chosen.
The practical reading is not that tretinoin fails in darker skin — the broader literature does not support that, and a 107-subject single-centre trial cannot settle it. The practical reading is that if you have Fitzpatrick IV–VI skin, the specific evidence for this specific product at this specific strength is absent, and the manufacturer says so instead of extrapolating for you.
Where the evidence stops
- Beyond 52 weeks of daily use, safety has not been established and has not been histologically investigated in controlled trials.
- In patients treated with the older 0.05% cream for longer than 48 weeks, there is evidence of atypical changes in melanocytes and keratinocytes and of increased dermal elastosis. The label states the relevance of this to 0.02% is unknown.
- Patients with visible actinic keratosis or a history of skin cancer were excluded from the trials — so the group with the most photodamage has no data.
- Neither safety nor efficacy for preventing or treating actinic keratoses or skin neoplasms has been established.
- Patients may lose some of the effect within 12 weeks of stopping.
- No study has compared 0.02% against the older 0.05% formulation for either efficacy or facial irritation.
That list is not a criticism of the product. It is the product telling you the boundary of what is known, which is the single most useful thing a label can do and the thing a compounded formula can never do, because there is no dossier behind it to draw the boundary from.
The price problem
Renova 0.02% has no approved generic. A 40 g tube runs about $319 cash. Generic tretinoin cream — the same molecule, typically 0.025%, in a non-emollient base — starts around $38, and is frequently covered when it is prescribed for acne rather than wrinkles.
What the extra money buys is a vehicle designed for tolerability and an indication written for the thing you actually want treated. Neither is worthless. But the label itself concedes that the emollient formulation has never been compared head-to-head against the standard one, so the tolerability advantage is a design intention rather than a measured result. If you are paying cash, that is an expensive intention.
If you are considering it
- Read the indication paragraph before you buy anything else in this category. It recalibrates the whole market.
- Ask your prescriber what generic tretinoin would cost you, and whether the emollient base is worth the difference in your case.
- Budget six months. The trials ran 24 weeks, and the improvement bands were read at the end of them.
- Wear sunscreen daily and avoid sun. Every arm of every trial, including the vehicle arm, was doing this — it is not an optional extra, it is part of the treatment that was tested.
- Do not expect anything for coarse wrinkles, laxity or mottled pigmentation. Those endpoints were measured and did not replicate.
- If you stop, expect to lose ground within about three months.
- If you have Fitzpatrick IV–VI skin, discuss the subgroup finding with your prescriber rather than assuming it applies or does not.
Where we stand
At 72, Renova scores lower than several compounded products in this register whose evidence is far weaker — and that is the correct outcome of an honest scoring model, not a fault in it. Renova is marked down for a small effect and a bad price. It is marked up, hard, for being the only product here that publishes the trials that failed, the arm that got no drug and the population where it lost.
The value of this review is mostly comparative. When a compounded formula promises to reverse photoageing on the strength of a day-30 satisfaction survey, the reply is not that the claim is implausible. The reply is that the same molecule, taken through actual controlled trials, produced a moderate result in one subject in ten at six months, and the company that ran those trials was required to print a denial of the exact claim being made.
The compounded photoageing formula we rated highest — read its 91%-by-day-30 figure against Renova's 24-week bands.
The same indication, compounded, with the concentration behind a consultation.
Why the vehicle arm is the number that matters.
Who this is for
- Someone who wants the one topical a regulator has actually approved for facial wrinkles, and wants to read the trial data before starting.
- Someone who will pair it with daily sunscreen and sun avoidance, which is the regimen every trial arm was on.
- Someone who prefers a fixed tube and a prescription to a rolling monthly charge.
- Someone whose skin has not tolerated 0.025% or higher and who wants a lower rung that is still a real drug.
- Anyone about to buy a compounded 'anti-ageing' formula who should read this label first as a calibration exercise.
- You are pregnant, planning pregnancy or breastfeeding.
- You want coarse wrinkles, laxity or mottled pigmentation treated — this label explicitly does not claim any of them.
- You have Fitzpatrick IV–VI skin and want evidence this will help, because the only trial in that group did not show it.
- You have actinic keratoses or a history of skin cancer — those patients were excluded from the trials.
- You would be paying cash and generic tretinoin is available to you, unless the emollient vehicle is the specific thing you need.
- You want a product proven safe for indefinite daily use. Fifty-two weeks is where the evidence stops.
We earn nothing on this link. Before you buy the brand, ask your prescriber what generic tretinoin 0.025% cream would cost you — it is the same molecule at a slightly higher strength.
This is an editorial assessment of published information about a prescription product. It is not a diagnosis, not a prescription and not a substitute for your own prescriber. Hydroquinone and tretinoin are drugs. Decisions about them belong with a clinician who has seen your skin.
Sources
- S-01FDA-approved labelling — RENOVA (tretinoin) cream 0.02%, Bausch Health US LLC The indication statement including the capitalised denial; the five-trial programme and the 24-week improvement bands (worsened 1%/3%, no change 40%/58%, minimal 35%/27%, mild 15%/9%, moderate 10%/3%); the Fitzpatrick IV–VI single-centre result of 29% against 43%; the 52-week limit; the exclusion of actinic keratosis and skin cancer patients; the loss of effect within 12 weeks of stopping; and the absence of any comparison against the 0.05% formulation. Read 2 August 2026.
- S-02Renova prescribing information portal — Ortho Dermatologics Brand availability and prescription-only status.
- S-03GoodRx — Renova pricing Cash pricing for the 40 g tube and the absence of an approved generic at 0.02%. Retrieved 2 August 2026.
- S-04GoodRx — Retin-A and generic tretinoin pricing The generic tretinoin comparator used in the value assessment — cash prices starting around $38. Retrieved 2 August 2026.